The Medical Letter on Drugs and Therapeutics
Miltefosine (Impavido) for Leishmaniasis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved miltefosine (Impavido – Knight Therapeutics), an oral alkylphosphocholine analog, for treatment of visceral, cutaneous, and mucosal leishmaniasis caused by some Leishmania species. It is the first drug to be approved by the FDA for treatment of cutaneous and mucosal leishmaniasis and the first oral drug to be approved for treatment of visceral leishmaniasis.

LEISHMANIASIS — Leishmania parasites are transmitted to humans through sand fly bites. The disease occurs primarily in the tropics, subtropics, and southern Europe; most US patients become infected overseas. Cutaneous leishmaniasis usually presents as an ulcerative skin lesion at the site of the sand fly bite. The lesion usually resolves spontaneously within several months, but generally leaves a scar. Some New World (Western Hemisphere) Leishmania species may disseminate from the skin to ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Miltefosine (Impavido) for Leishmaniasis
Article code: 1451d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian